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INTRODUCTION
1Department of Internal Medicine, 2Department of Rheumatology, Lehigh Valley Health Network, Allentown, Pennsylvania
•  Primary angiitis of the CNS (PACNS) is a rare vasculitis that is particularly 
challenging to diagnose. 
•  It should be considered in the setting of recurrent strokes, continued cognitive 
decline, and recurrent or progressive focal neurological deficits. 
•  It is essentially a diagnosis of exclusion after ruling out systemic involvement with 
confirmatory cerebrovascular imaging or histopathological evidence of vasculitis.1 
•  Current treatment recommendations include high dose corticosteroids and 
cyclophosphamide. Limited data supports the use of rituximab in refractory cases of 
PACNS.2,3 
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CASE
•  Our patient is a 56-year-old male with recurrent multifocal cerebral infarcts, 
encephalopathy and seizures secondary to PACNS diagnosed a year prior with 
cerebral arteriogram. 
•  He presented with worsening right sided weakness, expressive aphasia, and urinary 
incontinence.
•  MRI upon admission revealed new areas of acute/subacute infarctions in the basal 
ganglia and corona radiata. 
•  Lumbar puncture was unremarkable. Other labs confirmed no underlying systemic 
vasculitis with negative ANA and ANCA profiles. Renal biopsy showed diabetic 
nephropathy without signs of connective tissue disease. 
•  Cerebral arteriogram was repeated, showing multiple small peripheral arterial 
narrowing and beading consistent with a diagnosis of PACNS.
•  Despite increasing IV corticosteroids and treatment with Cytoxan for over 6 months, 
our patient continued to demonstrate decline. 
•  During the hospital course, Rituxan infusions were initiated and patient began to 
show clinical improvement over the following 6 weeks. He unfortunately regressed 
after a few months of treatment.
DISCUSSION
•  Most patients with PACNS demonstrate improvement in symptoms and on imaging 
when trialed on steroids with or without Cytoxan.
•  No studies suggest an optimal treatment regimen or duration. 
•  Three case reports in the current literature describe clinical and radiographic 
improvement in adults with PACNS after treatment with rituximab.2,3
•  In one case where the diagnosis was made by angiographic findings and an 
abnormal CSF, rituximab was given as first-line therapy.2
•  In the other two cases, the diagnosis of PACNS was histopathological with evidence 
of a lymphocytic vasculitic process involving the brain and spinal cord. Rituximab 
was used as first-line in one and after failing Cytoxan in the other.2
•  Our patient was deemed to have failed Cytoxan and unfortunately Rituxan. 
•  This case shows the difficulty of diagnosing PACNS. The goal standard for the 
diagnosis of PACNS is a brain biopsy. 
•  Only a positive biopsy can ascertain the diagnosis which we did not have. Staining, 
immunohistochemistry studies, and immunophenotyping are needed to rule out other 
mimickers.  
•  Refractory cases are rare and require reconsidering the diagnosis. 
